down arrow

Merck & Co., Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US58933Y1055
USD
100.89
-1.38 (-1.35%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

100.56102.08

52 Week

73.31105.84
Valuation
Technical
Day's Volume

CASH

2.55 M

Shareholding (Mar 2025)

FII

18.09%

Held by 720 FIIs

DII

50.9%

Held by 240 DIIs

Promoter

0.08%

How big is Merck & Co., Inc.?

22-Jun-2025

As of Jun 18, Merck & Co., Inc. has a market capitalization of $278.9 billion, with net sales of $63.8 billion and net profit of $17.5 billion over the latest four quarters.

As of Jun 18, Merck & Co., Inc. has a market capitalization of 278,896.88 million, classifying it as a Large Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 63,783.00 million, while the sum of Net Profit for the same period is 17,452.00 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 46,313.00 million and Total Assets amounting to 117,106.00 million.

Read More

What does Merck & Co., Inc. do?

22-Jun-2025

Merck & Co., Inc. is a global healthcare company that provides prescription medicines, vaccines, biologic therapies, and animal health products. As of March 2025, it reported net sales of $15.6 billion and a market cap of approximately $278.9 billion.

Overview:<BR>Merck & Co., Inc. is a global healthcare company operating in the Pharmaceuticals & Biotechnology industry, offering health solutions through prescription medicines, vaccines, biologic therapies, and animal health products.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 15,619 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 5,085 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 278,896.88 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00 <BR>Dividend Yield: 5.82% <BR>Debt Equity: 0.53 <BR>Return on Equity: 40.02% <BR>Price to Book: 5.77 <BR><BR>Contact Details:<BR>Address: 2000 Galloping Hill Rd, KENILWORTH NJ: 07033-1310 <BR>Tel: 1 908 7404000 <BR>Website: http://www.merck.com/

Read More

Who are in the management team of Merck & Co., Inc.?

22-Jun-2025

As of March 2022, Merck & Co., Inc.'s management team includes Kenneth Frazier as Chairman, President, and CEO, and Leslie Brun as Lead Independent Director, along with independent directors Thomas Cech, Mary Coe, Pamela Craig, and Thomas Glocer.

As of March 2022, the management team of Merck & Co., Inc. includes Mr. Kenneth Frazier, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Leslie Brun as the Lead Independent Director, along with independent directors Dr. Thomas Cech, Ms. Mary Coe, Ms. Pamela Craig, and Mr. Thomas Glocer.

Read More

Is Merck & Co., Inc. overvalued or undervalued?

20-Oct-2025

As of October 17, 2025, Merck & Co., Inc. is considered undervalued with a P/E ratio of 15 compared to the peer average of 26.1, a strong growth potential indicated by a PEG ratio of 0.03, and a competitive EV to EBITDA ratio of 11.50, despite recent stock underperformance and a robust ROE of 40.02% and dividend yield of 5.70%.

As of 17 October 2025, the valuation grade for Merck & Co., Inc. moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued given its P/E ratio of 15, which is lower than the peer average of approximately 26.1 for comparable companies like Johnson & Johnson and Eli Lilly & Co. Additionally, Merck's PEG ratio stands out at 0.03, suggesting strong growth potential relative to its price, while its EV to EBITDA ratio of 11.50 is competitive against peers like Pfizer, which has an EV to EBITDA of 11.07.<BR><BR>In terms of performance, Merck's recent stock returns have lagged behind the S&P 500, with a year-to-date decline of 14.77% compared to the index's gain of 13.30%. This underperformance, coupled with a robust ROE of 40.02% and a dividend yield of 5.70%, reinforces the narrative that Merck is currently undervalued in the market.

Read More

Is Merck & Co., Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Merck & Co., Inc. shows a mildly bullish trend on daily and weekly charts, despite mixed signals from MACD indicators and underperforming the S&P 500 with year-to-date and one-year returns of -15.70% and -17.69%, respectively.

As of 31 October 2025, the technical trend for Merck & Co., Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, driven by a mildly bullish MACD on the daily timeframe and mildly bullish moving averages. However, the weekly MACD is mildly bullish while the monthly MACD remains bearish, indicating mixed signals across different timeframes. Additionally, the Dow Theory shows a mildly bearish signal on the weekly chart but is mildly bullish on the monthly chart. <BR><BR>In terms of performance, Merck has underperformed the S&P 500 across multiple periods, with a year-to-date return of -15.70% compared to the S&P 500's 16.30%, and a one-year return of -17.69% versus 19.89% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 22.52%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.58 times

 
3

The company has declared Positive results for the last 4 consecutive quarters

4

With ROCE of 29.98%, it has a attractive valuation with a 4.16 Enterprise value to Capital Employed

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 298,483 Million (Large Cap)

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

5.44%

stock-summary
Debt Equity

0.55

stock-summary
Return on Equity

38.86%

stock-summary
Price to Book

6.09

Revenue and Profits:
Net Sales:
15,800 Million
(Quarterly Results - Jun 2025)
Net Profit:
4,428 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.04%
0%
20.04%
6 Months
28.9%
0%
28.9%
1 Year
-0.47%
0%
-0.47%
2 Years
-3.97%
0%
-3.97%
3 Years
-8.32%
0%
-8.32%
4 Years
37.56%
0%
37.56%
5 Years
29.13%
0%
29.13%

Merck & Co., Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Merck & Co., Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Merck & Co., Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, driven by a mildly bullish MACD on the daily timeframe and mildly bullish moving averages. However, the weekly MACD is mildly bullish while the monthly MACD remains bearish, indicating mixed signals across different timeframes. Additionally, the Dow Theory shows a mildly bearish signal on the weekly chart but is mildly bullish on the monthly chart. In terms of performance, Merck has underperformed the S&P 500 across multiple periods, with a year-to-date return of -15.70% compared to the S&P 500's 16.30%, and a one-year return of -17.69% versus 19.89% for the index....

Read More

Is Merck & Co., Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Merck & Co., Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is mildly bullish, supported by a bullish daily moving average. However, the monthly MACD and KST remain bearish, indicating mixed signals across different time frames. The Bollinger Bands show a mildly bullish stance on the weekly chart but are mildly bearish on the monthly chart. Dow Theory confirms a mildly bullish trend in both weekly and monthly perspectives. In terms of performance, Merck has underperformed the S&P 500 across multiple periods, with a year-to-date return of -17.08% compared to the S&P 500's 16.30%, and a one-year return of -19.03% versus 19.89%. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish indicators on the monthly charts....

Read More

Is Merck & Co., Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Merck & Co., Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The daily moving averages indicate a bullish stance, and the weekly KST is bullish, supporting the mildly bullish outlook. However, the monthly indicators, including the Bollinger Bands and KST, are bearish, which tempers the overall strength of the bullish signal. In terms of performance, Merck has underperformed against the S&P 500 across multiple time frames, with a year-to-date return of -13.57% compared to the S&P 500's 16.30%, and a one-year return of -15.97% versus 19.89% for the index....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
6.20%
EBIT Growth (5y)
9.91%
EBIT to Interest (avg)
14.83
Debt to EBITDA (avg)
1.58
Net Debt to Equity (avg)
0.53
Sales to Capital Employed (avg)
0.77
Tax Ratio
13.47%
Dividend Payout Ratio
46.32%
Pledged Shares
0
Institutional Holding
81.18%
ROCE (avg)
22.52%
ROE (avg)
31.91%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
5.82
EV to EBIT
13.86
EV to EBITDA
11.50
EV to Capital Employed
4.16
EV to Sales
4.81
PEG Ratio
0.03
Dividend Yield
5.70%
ROCE (Latest)
29.98%
ROE (Latest)
40.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 302 Schemes (30.89%)

Foreign Institutions

Held by 720 Foreign Institutions (18.09%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 1.16% vs 2.13% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -12.92% vs 35.78% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15,800.00",
          "val2": "15,619.00",
          "chgp": "1.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7,415.00",
          "val2": "7,809.00",
          "chgp": "-5.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "305.00",
          "val2": "313.00",
          "chgp": "-2.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,000.00",
          "val2": "-631.00",
          "chgp": "-58.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4,428.00",
          "val2": "5,085.00",
          "chgp": "-12.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "402.50%",
          "val2": "429.60%",
          "chgp": "-2.71%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.85% vs 2.39% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 4,444.56% vs -97.40% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "63,973.00",
          "val2": "59,871.00",
          "chgp": "6.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "25,143.00",
          "val2": "6,854.00",
          "chgp": "266.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1,271.00",
          "val2": "1,146.00",
          "chgp": "10.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,179.00",
          "val2": "-1,029.50",
          "chgp": "-14.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "17,133.00",
          "val2": "377.00",
          "chgp": "4,444.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "322.70%",
          "val2": "49.80%",
          "chgp": "27.29%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
15,800.00
15,619.00
1.16%
Operating Profit (PBDIT) excl Other Income
7,415.00
7,809.00
-5.05%
Interest
305.00
313.00
-2.56%
Exceptional Items
-1,000.00
-631.00
-58.48%
Consolidate Net Profit
4,428.00
5,085.00
-12.92%
Operating Profit Margin (Excl OI)
402.50%
429.60%
-2.71%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 1.16% vs 2.13% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -12.92% vs 35.78% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
63,973.00
59,871.00
6.85%
Operating Profit (PBDIT) excl Other Income
25,143.00
6,854.00
266.84%
Interest
1,271.00
1,146.00
10.91%
Exceptional Items
-1,179.00
-1,029.50
-14.52%
Consolidate Net Profit
17,133.00
377.00
4,444.56%
Operating Profit Margin (Excl OI)
322.70%
49.80%
27.29%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 6.85% vs 2.39% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 4,444.56% vs -97.40% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Merck & Co., Inc. stock-summary
stock-summary
Merck & Co., Inc.
Pharmaceuticals & Biotechnology
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.
Company Coordinates stock-summary
Company Details
2000 Galloping Hill Rd , KENILWORTH NJ : 07033-1310
stock-summary
Tel: 1 908 7404000
stock-summary
http://www.merck.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."